Tagged with ALS

Pharma Anna Van Poucke, Partner and Chairman at KPMG Healthcare in the Netherlands, explains how KPMG can helps its partners and clients move forward towards a better integrated, more efficient and smartly designed healthcare eco-system, while remaining at the forefront of the industry in terms of M&A, supply chain and cultural…

Pharma Alberto Gugliemo, President of the Carlo Besta Institute in Milan, shares the changing perception of neurological diseases and neurological science in Italy, the nature of the institute’s collaboration with the industry and the importance of easing regulations surrounding the hire of scientists. As president of Italy’s leading scientific institute for…

Pharma Francesco Carugi, Managing Director at Grifols Italy, discusses the company’s presence in the plasma, plasma products and plasma diagnostics segments, the impact of the liberalization of the Italian plasma market on their growth and business model and his commitment to driving change management to develop the affiliate’s future success. Grifols is…

Pharma As the founder of Egypt’s leading commercial agent for advanced medical technologies, Mahmoud Bagneid has a simple goal for Egyptian healthcare; for all Egyptian’s to be aware that they should have a yearly heath checkup, and to have regular basic blood tests to diagnose diabetes, hypertension, and other common health…

Pharma Daniel de Labauve d’Arifat discusses how to accomplish the new Mauritian government’s Vision 2030 strategy, his company’s successful track record as the main wholesaler and distributor of pharmaceuticals on the island, and the Mauritian business environment. As articulated in the Prime Minister’s recent Vision 2030 speech, the new government wants to…

Pharma Egypt is at the ‘golden stage’ for investment, claims Boehringer Ingelheim country head Mohamed El-Sahhar, who explains how the company is expanding their organization in Egypt ahead of an expansion into diabetes and oncology.  Egypt’s international image is still heavily influenced by the political instability of 2011 to 2013; what…

Pharma Amgen Netherlands is preparing to launch five new products next year, including their leading cardiovascular biotech product Repatha and recently announced the acquisition of the Dutch biotech Dezima. General manager Jasper van Grunsven explains the challenges of preparing for the upcoming year in the midst of structural changes to the…

Pharma Philippe Luscan reveals how Sanofi contributes almost USD 6.35 billion net to the French economy; how their five new global business units will drive future growth, and why they are now accelerating their investment in biologics. As the national champion in the healthcare sector, what is the importance of Sanofi…

Pharma Christian Deleuze reveals the impact of the acquisition by Sanofi in 2011; explains the profitability and global reach of the bio manufacturing facility in Lyon; and tells us that the current system does not capture the benefits that the next generation of gene therapy products deliver over time, transforming chronic diseases into…

Pharma Novasep is the largest contract manufacturer for the pharmaceuticals and fine chemicals industries in France. Michel Spagnol, the company’s chairman and CEO, highlights recent reorganization and “back to basics” strategy based on organic growth improving the product mix and underscoring new investments. What is your perspective regarding the state of…

Pharma Lyon provides companies with a flamboyant and collaborative environment to develop. Bruno Masurel, Head of the International Division of the local Chamber of Commerce talks about the advantages the region offers and the services the institution has to help companies go international. Could you please explain the reasons behind the…

Pharma Dr. Giorgio Pisani, President and CEO of IBSA Italy, talks about his founding of the company in 2001 and its rapid growth in the market through a combination of organic growth and acquisitions, as well as the current direction of the IBSA group and his ambitions for the company in…